![INDEX [assets.cambridge.org]Aachen and Lothar IV ofFrance and Ottonians , , , , , Aachen capitulary Aachen Gospels , , , ,](https://static.fdocuments.in/doc/165x107/60b8d200380fd66cca378262/index-aachen-and-lothar-iv-offrance-and-ottonians-aachen-capitulary.jpg)
Aachen Resonance Biotronik
3
Aachen Resonance GmbH Pauwelsstrasse 19, 52074 Aachen, Tel. +49-(0)241-97900905, Fax +49-(0)241-97900907, E-Mail: [email protected] Press Release Aachen, Germany, 14.01.2009 Aachen Resonance announces for 2009 the distribution of the ELUTAX, Drug eluting Balloon, through Biotronik sales in Switzerland, Belgium, Netherland, Luxemburg, England, Ireland and Italy. BIOTRONIK is especially present in these markets offering products for diagnosis, treatment and in the areas of cardiac rhythm management, electrophysiology, and vascular intervention. The main application of Drug eluting Balloons is restenosis of vascular lesions after angioplasty or stent placement, restenosis occurs in 5 to 30% of treatments. The restenosis is caused by neointimal cell hyperplasia. Local administration of lipophilic taxane compounds can inhibit the proliferation of such cells for a long period. The Aachen Resonance Elutax Drug eluting Balloon is developed especially for coronary arteries and venous by- pass as well as for small vessels in peripheral and supraaortic regions. The balloon is coated with 2 microgram/mm 2 of pure Paclitaxel. The drug surface contains two layers. The Base coating to ensure the Drug attachment (consistency of ICE) and the Top coating (consistency of SNOW). No polymer, nor any other agent are used to ensure the Drug attachment. The SNOW Layer is responsible for the Drug uptake as it releases the Drug in appropriate conditions for an effective penetration into the vessel wall.
-
Upload
alexander001 -
Category
Documents
-
view
840 -
download
0
description
Aachen Resonance announces for 2009 the distribution of the ELUTAX, Drug eluting Balloon, through Biotronik sales in Switzerland, Belgium, Netherland, Luxemburg, England, Ireland and Italy.
Transcript of Aachen Resonance Biotronik
Aachen Resonance GmbH
Pauwelsstrasse 19, 52074 Aachen, Tel. +49-(0)241-97900905, Fax +49-(0)241-97900907, E-Mail: [email protected]
Press Release
Aachen, Germany, 14.01.2009
Aachen Resonance announces for 2009 the distribution of the ELUTAX, Drug eluting Balloon, through Biotronik sales in Switzerland, Belgium, Netherland, Luxemburg, England, Ireland and Italy.BIOTRONIK is especially present in these markets offering products for diagnosis, treatment and in the areas of cardiac rhythm management, electrophysiology, and vascular intervention.
The main application of Drug eluting Balloons is restenosis of vascular lesions after angioplasty or stent placement, restenosis occurs in 5 to 30% of treatments. The restenosis is caused by neointimal cell hyperplasia. Local administration of lipophilic taxane compounds can inhibit the proliferation of such cells for a long period.
The Aachen Resonance Elutax Drug eluting Balloon is developed especially for coronary arteries and venous by-pass as well as for small vessels in peripheral and supraaortic regions. The balloon is coated with 2 microgram/mm2 of pure Paclitaxel.
The drug surface contains two layers. The Base coating to ensure the Drug attachment (consistency of ICE) and the Top coating (consistency of SNOW). No polymer, nor any other agent are used to ensure the Drug attachment.
The SNOW Layer is responsible for the Drug uptake as it releases the Drug in appropriate conditions for an effective penetration into the vessel wall.
About Aachen Resonance:
Aachen Resonance is a leading European manufacturer of medical technology with a worldwide market presence. The company offers a complete line of products for treatment and advanced therapy support in
vascular intervention, working in close cooperation with the University of Technology in Aachen.
Its main focus is developing new devices with improved biocompatibility
The field of vascular intervention consists of balloon catheters, stents, drug eluting stents and drug eluting balloons for coronary and peripheral applications.
The company invests heavily in research and development, and is pursuing important, future-oriented approaches to cardiovascular therapy. Currently, Aachen Resonance maintains three headquarters in Europe for research, development and manufacturing.
Aachen Resonance is market leader in Europe for Drug eluting balloons.
Contact address:
Dr. Alexander Ruebben, CEO
Aachen Resonance GmbHPauwelsstrasse 19D-52074 Aachen Germany
Tel. 0049 241 97900905Fax. 0049 241 97900907www.aachen-resonance.comEmail: [email protected]
